Carfilzomib Associated With Cardiotoxicity Risk in Multiple Myeloma

Article

Cardiovascular adverse events are more than twice as frequent in carfilzomib arms of randomized controlled trials in multiple myeloma, according to a systematic review and meta-analysis of 24 studies.

Cardiovascular adverse events (CVAEs) are more than twice as frequent in carfilzomib arms of randomized controlled trials and may go underdetected in phase I trials, according to a systematic review and meta-analysis of 24 studies of patients with multiple myeloma (abstract 8018) presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 2–6 in Chicago.

“Carfilzomib CVAEs occurred in 18% and 8% of patients (all-grade and high-grade, respectively),” reported lead study author Adam Justin Waxman, MD, of the Abramson Cancer Center in Philadelphia, and colleagues. “Higher doses of carfilzomib are associated with more high-grade CVAEs (6.4% vs 11.9%).”

The most frequent of these were heart failure and hypertension, the team reported. Elevated rates of arrhythmia, ischemia, and cardiac arrest were all also associated with carfilzomib treatment (Ps < .001), the meta-analysis concluded.

Undifferentiated edema (affecting 25% of patients) and dyspnea (24%) were also frequent although it was not clear that these were always specific to CVAE, the authors cautioned.

The authors pooled data from five phase I, eight phase I/II, eight phase II, and three phase III clinical trials for analysis. The majority of the patients represented in the studies analyzed (n = 2,203) had relapsed/refractory multiple myeloma; 391 patients were newly diagnosed. Most (2,019) were age 60–65 years; 251 were 60 years old or younger at the time of trial participation and 324 were older than 65 years.

Researchers should seek to identify patients at high risk for CVAEs and to develop “optimal monitoring strategies,” as well as to evaluate treatments that might reduce the risk of CVAEs among patients with multiple myeloma, the authors concluded.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Related Content